본문으로 건너뛰기
← 뒤로

p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism.

1/5 보강
Nature genetics 📖 저널 OA 50% 2024: 2/5 OA 2025: 7/12 OA 2026: 7/17 OA 2024~2026 2026 Vol.58(1) p. 116-131
Retraction 확인
출처

Laue K, Pozzi S, Zerbib J, Bertolio R, Eliezer Y, Cohen-Sharir Y, Winkler T, Caputo M, Ricci AA, Adler L, Khoury R, Longobardi G, Slutsky R, Leikin-Frenkel AI, Ovadia S, Lange K, Rustighi A, Piazza S, Sacconi A, Magesh RY, Keller FN, Berthelet J, Schäffer A, Saad R, Israeli Dangoor S, Szczepanowska K, Barshack I, Liao Y, Malitsky S, Brandis A, Broggini T, Czabanka M, Shi W, Merino D, Watson EV, Blandino G, Erez A, Ashery-Padan R, Medyouf H, Bertero L, Del Sal G, Satchi-Fainaro R, Ben-David U

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.8%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Brain metastasis (BM) carries a poor prognosis, yet the molecular basis of brain tropism remains unclear.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Laue K, Pozzi S, et al. (2026). p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism.. Nature genetics, 58(1), 116-131. https://doi.org/10.1038/s41588-025-02446-1
MLA Laue K, et al.. "p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism.." Nature genetics, vol. 58, no. 1, 2026, pp. 116-131.
PMID 41461910 ↗

Abstract

Brain metastasis (BM) carries a poor prognosis, yet the molecular basis of brain tropism remains unclear. Analysis of breast cancer BM (BCBM) revealed pervasive p53 inactivation through mutations and/or aneuploidy, with pathway disruption already present in primary tumors. Functionally, p53 inactivation markedly increased BCBM formation and growth in vivo, causally linking p53 perturbation to BM. Mechanistically, p53 inactivation upregulated SCD1 and fatty acid synthesis (FAS), essential for brain-metastasizing cells; SCD1 knockout abolished the p53-dependent growth advantage. Molecularly, p53 suppressed SCD1 directly through promoter binding and indirectly by downregulating its co-activator DEPDC1. Astrocytes further enhanced FAS by secreting factors that were metabolized in a p53-dependent manner, promoting tumor survival, proliferation and migration. Finally, p53-deficient tumors were sensitive to FAS inhibition ex vivo and in vivo. Thus, we identify p53 inactivation as a driver of BCBM, reveal p53-dependent and astrocyte-dependent FAS modulation and highlight FAS as a therapeutically targetable BCBM vulnerability.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반